Omnio (Pharmaceuticals and Biotechnology) Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $1.53M

  • Investors
  • 2

Omnio (Pharmaceuticals and Biotechnology) General Information

Description

Developer of pharmaceutical therapeutic designed for wound healing and anti-infection management. The company develops recombinant human plasminogen that helps in wound healing and offers its product in the form of ear drops for tympanic membrane perforation, enabling people to get rid of irritations.

Contact Information

Website
www.omnio.se
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Uminova Science Park
  • Tvistevägen 48
  • 907 19 Umeaa
  • Sweden
+46 073-620
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech
Corporate Office
  • Uminova Science Park
  • Tvistevägen 48
  • 907 19 Umeaa
  • Sweden
+46 073-620

Omnio (Pharmaceuticals and Biotechnology) Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Omnio (Pharmaceuticals and Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 11-Aug-2022 $1.53M Completed Generating Revenue
3. Later Stage VC 06-Dec-2021 Completed Generating Revenue
2. Angel (individual) $5.07M $5.07M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Omnio (Pharmaceuticals and Biotechnology)’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Omnio (Pharmaceuticals and Biotechnology) Patents

  • 58

    Total Documents Applications and Grants

  • Total Patents Families

  • 27

    Granted

  • Pending

  • Expiring in next 12 mo

Omnio (Pharmaceuticals and Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180326023-A1 Plasminogen dosage regimen for wound healing Inactive 10-Nov-2015
US-20190365684-A1 Inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries Inactive 22-Sep-2015
EP-3352741-A1 Inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries Active 22-Sep-2015
EP-3352741-B1 Inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries Active 22-Sep-2015
US-20180280329-A1 Inhibitors of plasminogen for treating, reducing or preventing radiation-induced injuries Inactive 22-Sep-2015 A61K31/196
To view Omnio (Pharmaceuticals and Biotechnology)’s complete patent history, request access »

Omnio (Pharmaceuticals and Biotechnology) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Omnio (Pharmaceuticals and Biotechnology) Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Fort Knox (Umea) Family Office Minority
Umeå Biotech Incubator Accelerator/Incubator
To view Omnio (Pharmaceuticals and Biotechnology)’s complete investors history, request access »

Ready to get started?

Request a free trial

Omnio (Pharmaceuticals and Biotechnology) FAQs

  • When was Omnio (Pharmaceuticals and Biotechnology) founded?

    Omnio (Pharmaceuticals and Biotechnology) was founded in 2001.

  • Where is Omnio (Pharmaceuticals and Biotechnology) headquartered?

    Omnio (Pharmaceuticals and Biotechnology) is headquartered in Umeaa, Sweden.

  • What is the size of Omnio (Pharmaceuticals and Biotechnology)?

    Omnio (Pharmaceuticals and Biotechnology) has 6 total employees.

  • What industry is Omnio (Pharmaceuticals and Biotechnology) in?

    Omnio (Pharmaceuticals and Biotechnology)’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Omnio (Pharmaceuticals and Biotechnology) a private or public company?

    Omnio (Pharmaceuticals and Biotechnology) is a Private company.

  • What is Omnio (Pharmaceuticals and Biotechnology)’s current revenue?

    The current revenue for Omnio (Pharmaceuticals and Biotechnology) is .

  • How much funding has Omnio (Pharmaceuticals and Biotechnology) raised over time?

    Omnio (Pharmaceuticals and Biotechnology) has raised $7.21M.

  • Who are Omnio (Pharmaceuticals and Biotechnology)’s investors?

    Fort Knox (Umea) and Umeå Biotech Incubator have invested in Omnio (Pharmaceuticals and Biotechnology).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »